Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin
-- Shipment of vasopressin, a generic alternative to Vasostrict®, commences today, with 180 days of marketing exclusivity -- -- Product launch expected to drive significant revenue growth in 2022 -- WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the commercial availability of its recently…